One year of adjuvant olaparib is currently indicated either alone or concurrently with endocrine therapy in early breast cancer with BRCA1- or BRCA2-mutated high-risk patients that have received local treatment and neoadjuvant or adjuvant chemotherapy. The gene discussed is BRCA2; the disease is breast carcinoma.